Kyverna Therapeutics (NASDAQ:KYTX) Posts Quarterly Earnings Results, Meets Estimates

Kyverna Therapeutics (NASDAQ:KYTX) issued its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.68), FiscalAI reports.

Kyverna Therapeutics Stock Performance

KYTX stock traded down $0.09 during midday trading on Thursday, reaching $5.03. The company had a trading volume of 1,198,533 shares, compared to its average volume of 806,677. The firm has a market capitalization of $311.06 million, a PE ratio of -1.71 and a beta of 2.12. The stock has a 50 day moving average price of $6.28 and a 200 day moving average price of $7.90. Kyverna Therapeutics has a fifty-two week low of $4.49 and a fifty-two week high of $13.67. The company has a quick ratio of 9.06, a current ratio of 9.06 and a debt-to-equity ratio of 0.15.

Analyst Ratings Changes

KYTX has been the topic of several research analyst reports. Needham & Company LLC set a $25.00 price objective on Kyverna Therapeutics in a research note on Friday, September 25th. William Blair raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Benchmark reiterated a “buy” rating on shares of Kyverna Therapeutics in a research note on Friday, September 25th. HC Wainwright reissued a “buy” rating on shares of Kyverna Therapeutics in a report on Thursday, October 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.